Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3704 - Immunotherapy phase I trials in patients over 70 years with advanced solid tumours: The Gustave Roussy experience

Date

10 Sep 2017

Session

Poster display session

Topics

Cancers in Adolescents and Young Adults (AYA);  Geriatric Oncology;  Immunotherapy

Presenters

Hélène Herin

Citation

Annals of Oncology (2017) 28 (suppl_5): v403-v427. 10.1093/annonc/mdx376

Authors

H. Herin1, E. Castanon1, V. Dyevre2, S. Aspeslagh1, A. Marabelle1, S. Postel-Vinay1, A. Varga1, A. Gazzah1, V. Ribrag1, R. Bahleda1, J. Michot1, O. Mir1, C. Massard1, A. Hollebecque1, J. Soria1, C. Baldini1

Author affiliations

  • 1 Drug Development Department (ditep), Gustave Roussy Cancer Campus, 94805 - Villejuif/FR
  • 2 Biostatistics And Epidemiology, Institut Gustave Roussy, 94800 - Villejuif/FR
More

Resources

Abstract 3704

Background

More than half of new cases of cancer are diagnosed in patients over 65 years. However only few elderly patients have so far been included into trials, despite general awareness of the need. The revolution of immune checkpoint blocker development brings new hope in older patients because of clinical efficacy and low toxicity. Clinical indications are rising steadily but very few data are available in this population where co-morbidities, reduced functional reserve and immunosenescence may affect efficacy and tolerance.

Methods

All cases of patients enrolled in immunotherapy phase I trial between January 2012 and December 2016 in the Drug Development Department (DITEP) at Gustave Roussy were retrospectively reviewed. Case-control analysis was performed in a group of patients ≥ 70 years (elderly patients EP) matched to a group of patients < 70 years (younger patients YP) by trial and treatment dose. We compared cumulative incidence, grade and type of adverse events (AEs) and survival outcomes. Cumulative incidence was calculated according to Fine and Gray method and survivals using Kaplan-Meier method.

Results

Median age of EP and YP were respectively 75 (70 - 88) and 55 (22 - 70). Among the 46 EP and the 174 YP enrolled in 13 protocols, 10 (22%) and 23 (13%) patients experienced grade 3-4 AEs. Cumulative incidence of grade 1-2 AEs was significantly higher in EP versus YP (p 

Conclusions

Immune checkpoint blockade appears to be a practicable option of treatment for elderly patients. The toxicity and efficacy profiles appear similar to the ones in younger patients. Dedicated studies in this population are warranted.

Clinical trial identification

Legal entity responsible for the study

Gustave Roussy

Funding

None

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.